Repligen (NASDAQ:RGEN) Sets New 52-Week Low – Time to Sell?

Repligen Corporation (NASDAQ:RGEN)’s stock price reached a new 52-week low during trading on Friday . The stock traded as low as $109.50 and last traded at $114.06, with a volume of 2174671 shares trading hands. The stock had previously closed at $124.40.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. UBS Group decreased their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Weiss Ratings lowered shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Barclays decreased their price target on shares of Repligen from $175.00 to $145.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Roth Mkm assumed coverage on shares of Repligen in a research note on Friday, April 17th. They set a “buy” rating and a $160.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.93.

Repligen Price Performance

The firm has a market capitalization of $6.63 billion, a P/E ratio of 138.35, a price-to-earnings-growth ratio of 2.22 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. The business has a 50 day simple moving average of $123.16 and a two-hundred day simple moving average of $145.59.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same period in the previous year, the firm posted $0.44 EPS. The firm’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Repligen by 1.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after buying an additional 75 shares during the period. NewEdge Wealth LLC increased its position in shares of Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 75 shares during the period. UMB Bank n.a. increased its position in shares of Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 92 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after buying an additional 100 shares during the period. Finally, Coldstream Capital Management Inc. increased its position in shares of Repligen by 5.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 101 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.